Altimmune (ALT) Long-Term Debt Repayments (2013 - 2019)
Altimmune (ALT) reported Long-Term Debt Repayments of $105062.0 for Q4 2019, up 241.17% on a QoQ basis from $30795.0 in Q3 2019.
Altimmune (ALT) has 6 years of Long-Term Debt Repayments data on file, last reported at $105062.0 in Q4 2019.
- Quarterly Long-Term Debt Repayments changed N/A year-over-year to $105062.0 in Q4 2019, while the trailing twelve-month figure through Dec 2020 was $135857.0 (changed 0.0% YoY) and the FY2020 annual result came in at $632000.0, up 116.44% from the prior year.
- Long-Term Debt Repayments advanced to $105062.0 in Q4 2019 per ALT's latest filing, from $30795.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $105062.0 in Q4 2019 and bottomed at -$250009.0 in Q3 2015.
- The 4-year median for Long-Term Debt Repayments is $8017.0 (2016), against an average of -$64639.6.
- The widest annual swing landed in 2015, when Long-Term Debt Repayments retreated 0.0%; it then surged 15995.96% in 2017.
- Tracing ALT's Long-Term Debt Repayments over 4 years: stood at -$250009.0 in 2015, then soared by 132.4% to $80999.0 in 2016, then sank by 80.33% to $15935.0 in 2017, then jumped by 559.32% to $105062.0 in 2019.
- Per Business Quant, the three latest ALT Long-Term Debt Repayments figures stand at $105062.0 (Q4 2019), $30795.0 (Q3 2019), and $15935.0 (Q2 2017).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 105,062.00 |
| Dec 31, 2019 | 105,062.00 |
| Sep 30, 2019 | 30,795.00 |
| Sep 30, 2019 | 30,795.00 |
| Jun 30, 2017 | 15,935.00 |
| Jun 30, 2017 | 15,935.00 |
| Dec 31, 2016 | 80,999.00 |
| Dec 31, 2016 | 80,999.00 |
| Jun 30, 2016 | 99.00 |
| Jun 30, 2016 | 99.00 |
| Sep 30, 2015 | -250,009.00 |
| Sep 30, 2015 | -250,009.00 |
| Jun 30, 2015 | -249,999.00 |
| Jun 30, 2015 | -249,999.00 |
| Mar 31, 2015 | -249,999.00 |
| Mar 31, 2015 | -249,999.00 |
| Dec 31, 2014 | -249,999.00 |
| Dec 31, 2014 | -249,999.00 |
| Sep 30, 2014 | -249,999.00 |
| Sep 30, 2014 | -249,999.00 |
| Jun 30, 2014 | -249,999.00 |
| Jun 30, 2014 | -249,999.00 |
| Mar 31, 2014 | -249,999.00 |
| Mar 31, 2014 | -249,999.00 |
| Dec 31, 2013 | -249,999.00 |
| Dec 31, 2013 | -249,999.00 |
| Sep 30, 2013 | -249,999.00 |
| Sep 30, 2013 | -249,999.00 |